U of M Medical School Research Led to FDA Approval of New Anti-obesity Medication for Adolescents

U of M Medical School Research Led to FDA Approval of New Anti-obesity Medication for Adolescents

One in five teenagers in the U.S. is afflicted with obesity and the prevalence continues to rise. That statistic could now change after research spearheaded by a University of Minnesota Medical School professor led to the approval of the first anti-obesity medication for adolescents in the U.S. in over 17 years. 

The U.S. Food and Drug Administration (FDA) approved an updated label for liraglutide (Saxenda®) injection 3.0 milligrams for use in the treatment of obesity in adolescents between the ages of 12 and 17 with a body weight above 60 kilograms (or 132 pounds) and an initial body mass index (BMI) corresponding to 30 kg/m2 or greater for adults. The treatment will be used as an adjunct to reduced-calorie meals and increased physical activity. 

Aaron S. Kelly, PhD, professor in the Department of Pediatrics and co-director of the Center for Pediatric Obesity Medicine at the U of M Medical School, was the international principal investigator and served as the signatory author for the phase 3 clinical trial that led to FDA approval. The study was published earlier this year in the New England Journal of Medicine and presented at Endo 2020, the Endocrine Societ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee